ADP-RIBOSE

作品数：59被引量：141H指数：6
导出分析报告
相关领域：医药卫生生物学更多>>
相关作者：李燕田永杰吕树卿尉蔚程介士更多>>
相关机构：山东大学上海医科大学东北师范大学华东师范大学更多>>
相关期刊：《Acta Biochimica et Biophysica Sinica》《Asian Journal of Andrology》《Journal of Integrative Plant Biology》《Advances in Modern Oncology Research》更多>>
相关基金：国家自然科学基金山东省科技发展计划项目山东省自然科学基金山东省医药卫生科技发展计划项目更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Synergistic effect of poly(ADP-ribose)polymerase(PARP)inhibitor with chemotherapy on CXorf67-elevated posterior fossa group A ependymoma
《Chinese Medical Journal》2024年第22期2770-2772,共3页Jichang Han Jianzhong Yu Meng Yu Yachao Liu Xiaomin Song Hao Li Lin Li 
supported by grants from the National Natural Science Foundation of China(Nos.92253303,92053201,and 82103123);the National Key Research and Development Program of China(No.2019YFA0802002);the China Postdoctoral Science Foundation(No.2021M703208).
To the Editor:Posterior fossa group A(PFA)ependymoma is one of the most common and aggressive pediatric tumors,which currently lacks effective chemotherapies.[1,2]Previously,we revealed CXorf67,which is specially unre...
关键词：drugs ELEVATED RENDER 
Poly (ADP-ribose): A double-edged sword governing cancer cell survival and death
《World Journal of Clinical Oncology》2024年第7期806-810,共5页Keun-Yeong Jeong Ji-Hyuk Kang 
Poly(ADP-ribose)(PAR),a polymer of ADP-ribose,is synthesized by PAR po-lymerase and is crucial for the survival of cancer cells due to its vital functions in DNA repair and post-translational modifications.Beyond its ...
关键词：ADP-RIBOSE Poly(ADP-ribose) ADP ribosylation PARylation Parthanatos ANTICANCER 
Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients
《World Journal of Clinical Oncology》2024年第7期848-858,共11页Naveed Syed Ashish Vittalrao Chintakuntlawar Deepti Vilasini Aisha Mohamed Al Salami Riad Al Hasan Imrana Afrooz Kanishka Uttam Chandani Ashok Uttam Chandani Aref Chehal 
BACKGROUND Poly(ADP-ribose)polymerase inhibitors(PARPis)are approved as first-line therapies for breast cancer gene(BRCA)-positive,human epidermal growth factor receptor 2-negative locally advanced or metastatic breas...
关键词：Homologous recombination repair BRCA1 BRCA2 Homologous recombination deficiency Ovarian cancer Breast cancer Poly(ADP-ribose)polymerase inhibitors OLAPARIB DNA double-strand breaks 
Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer:A network meta-analysis
《Cancer Pathogenesis and Therapy》2024年第2期81-90,共10页Mingqiang Shi Zhoujuan Li Guoshuang Shen Tianzhuo Wang Jinming Li Miaozhou Wang Zhen Liu Fuxing Zhao Dengfeng Ren Jiuda Zhao 
Background:Metastatic triple-negative breast cancer(mTNBC)is an aggressive histological subtype with poor prognosis.Several first-line treatments are currently available for mTNBC.This study conducted a network meta-a...
关键词：Metastatictriple-negativebreast cancer First-line treatment CHEMOTHERAPY Immune-checkpoint inhibitors Poly(ADP-Ribose)polymerase inhibitors AKT inhibitor Networkmeta-analysis 
Design,synthesis,and biological evaluation of novel chrysin derivatives as poly(ADP-ribose)polymerase 1(PARP1)inhibitors for the treatment of breast cancer
《Chinese Journal of Natural Medicines》2024年第5期455-465,共11页YANG Yao TONG Jing XIE Xianshun CAO Hong FU Yong LUO Yong LIU Shan CHEN Wen YANG Ning 
This work was supported by the Clinical Research Center for Breast&Thyroid Disease Prevention in Hunan Province(No.2018SK4001);the Scientific Research Project of Hunan Provincial Health Commission(No.20201969)。
In this study,we reported the discovery and structure-activity relationship analysis of chrysin derivatives as a new class of inhibitors targeting poly(ADP-ribose)polymerase 1(PARP1).Among these derivatives,compound 5...
关键词：Chrysin derivatives PARP1 Antitumor DNA damage Small molecules 
Recent advances in the treatment for gynecologic oncology
《Holistic Integrative Oncology》2024年第1期706-709,共4页Lei Li Jinghe Lang 
supported by the State Key Laboratory for Complex,Severe and Rare Diseases in Peking Union Medical College Hospital。
This commentary summarized the most important findings in the first half 2023 year based on Society of Gynecologic Oncology(SGO)annual meeting and publications in crucial journals.This commentary provided a comprehens...
关键词：Gynecologic cancer Targeted therapy IMMUNOTHERAPY PD-1 blockage Poly(ADP-Ribose)polymerase inhibitors 
A boost or a redundancy?on the value of combination of androgen receptor signal inhibitor and PARP inhibitor for advanced prostate cancer
《Holistic Integrative Oncology》2024年第1期219-230,共12页Qihao Wang Jianjun Ye Lei Zheng Xiang Tu Hao Zeng Yige Bao Qiang Wei 
Poly(ADP-ribose)polymerase(PARP)inhibitor(PARPi),as a novel endocrine therapy,has been investigated in patients with metastatic castration-resistant prostate cancer(mCRPC)in recent years.Multiple large-scale clinical ...
关键词：Poly(ADP-ribose)polymerase inhibitors Androgen receptor signaling inhibitor Castration-resistant prostate cancer Homologous recombination repair mutation 
Mechanism of PARP inhibitor resistance and potential overcoming strategies
《Genes & Diseases》2024年第1期306-320,共15页Xiaoyu Fu Ping Li Qi Zhou Ruyuan He Guannan Wang Shiya Zhu Amir Bagheri Gary Kupfer Huadong Pei Juanjuan Li 
PARP inhibitors(PARPi)are a kind of cancer therapy that targets poly(ADP-ribose)polymerase.PARPi is the first clinically approved drug to exert synthetic lethality by obstruct-ing the DNA single-strand break repair pr...
关键词：Drug resistance Homologous recombination PARP PARP inhibitor Poly(ADP-ribose)polymerase 
Transient HSP90 inhibition enhances the sensitivity of mantle cell lymphoma to poly(ADP-ribose)polymerase(PARP)inhibitors
《Genes & Diseases》2023年第5期1791-1794,共4页Chaowen Shi Dewan Ren Yufeng Gao Ya-Mei Dang Zhigang Tu Hanqing Liu 
supported by the National Natural Science Foundation of China(No.81672582 to HL,31771521 to ZT,and 82200083 to CS),Top Talent of Innovative Research Team of Jiangsu Province,China(to HL and ZT);the Natural Science Foundation of Jiangsu Province,China(No.BK20200891 to CS);the Senior Talent Start-up Funds of Jiangsu University(China)(No.14JDG050 and 14JDG011 to HL and ZT).
Mantle cell lymphoma(MCL)is an aggressive subtype of non-Hodgkin lymphoma(NHL)characterized by the overexpression of cyclin D1 and deregulated cell cycle.1 Ganetespib(STA-9090),a second-generation HSP90 inhibitor,dram...
关键词：LYMPHOMA PARP sized 
Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency
《Genomics, Proteomics & Bioinformatics》2023年第5期962-975,共14页Wenbin Li Lin Gao Xin Yi Shuangfeng Shi Jie Huang Leming Shi Xiaoyan Zhou Lingying Wu Jianming Ying 
supported by the National Key R&D Program of China(Grant No.2022YFC2409902);the National Natural Science Foundation of China(Grant No.82172876);the Beijing Nova Program of Science and Technology(Grant No.Z191100001119095);the Chinese Academy of Medical Sciences(CAMS)Innovation Fund for Medical Sciences(Grant No.2021-I2M-1-066);the Beijing Hope Run Special Fund of Cancer Foundation of China(Grant No.LC2019L04).
Defects in genes involved in the DNA damage response cause homologous recombination repair deficiency(HRD).HRD is found in a subgroup of cancer patients for several tumor types,and it has a clinical relevance to cance...
关键词：DNA damage response Homologous recombination repair deficiency Poly(ADP-ribose)polymerase inhibitor BIOMARKER HARMONIZATION 
全选清除导出
共6页<123456>
检索报告 对象比较 聚类工具 使用帮助 返回顶部